In vivo efficacy of the ketolide ABT-773 (cethromycin) against enterococci in a mouse peritonitis model

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 8, 2003, Pages 2706-2709

  Pai, Suresh R ^a   Singh, Kavindra V ^a   Murray, Barbara E ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETHROMYCIN; ERYTHROMYCIN; KETOLIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC SENSITIVITY; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; FEMALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PERITONITIS; PRIORITY JOURNAL; STRAIN DIFFERENCE;

ANIMALS; COLONY COUNT, MICROBIAL; ENTEROCOCCUS FAECIUM; ERYTHROMYCIN; GRAM-POSITIVE BACTERIAL INFECTIONS; KETOLIDES; LETHAL DOSE 50; MICE; MICE, INBRED ICR; MICROBIAL SENSITIVITY TESTS; PERITONITIS;

EID: 0041767388     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.8.2706-2709.2003     Document Type: Article

References (18)

1. Andrews, J. M., T. M. A. Weller, J. P. Ashby, R. M. Walker, and R. Wise. 2000. The in vitro activity of ABT-773, a new ketolide antimicrobial agent. J. Antimicrob. Chemother. 46:1017-1022.
2. Arduino, R. C., K. Jacques-Palaz, B. E. Murray, and R. M. Rakita. 1994. Resistance of Enterococcus faecium to neutrophil-mediated phagocytosis. Infect. Immun. 62:5587-5594.
3. Brueggemann, A. B., G. V. Doern, H. K. Huynh, E. M. Wingert, and P. R. Rhomberg. 2000. In vitro activity of ABT-773, a new ketolide, against recent clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob. Agents Chemother. 44:447-449.
4. Kim, M. K., W. Zhou, P. R. Tessier, D. Xuan, M. Ye, C. H. Nightingale, and D. P. Nicolau. 2002. Bactericidal effect and pharmacodynamics of cethromycin (ABT-773) in a murine pneumococcal pneumonia model. Antimicrob. Agents Chemother. 46:3185-3192.
5. Murray, B. E. 2000. Vancomycin-resistant enterococcal infections. N. Engl. J. Med. 342:710-721.
6. Murray, B. E. 1997. Vancomycin-resistant enterococci. Am. J. Med. 102: 284-293.
7. Murray, B. E. 1990. The life and times of the enterococci. Clin. Microbiol. Rev. 3:46-65.
8. Murray, B. E., and B. Mederski-Samoraj. 1983. Transferable β-lactamase: a new mechanism for in vitro penicillin resistance in Streptococcus faecalis. J. Clin. Investig. 72:1168-1171.
9. Murray, B. E., K. V. Singh, R. P. Ross, J. D. Heath, G. M. Dunny, and G. M. Weinstock. 1993. Generation of restriction map of Enterococcus faecalis OG1 and investigation of growth requirements and regions encoding biosynthetic function. J. Bacteriol. 175:5216-5223.
10. National Committee for Clinical Laboratory Standards. 2000. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically - fifth edition; approved standard. NCCLS document M7-A5. National Committee for Clinical Laboratory Standards, Wayne, Pa.
11. National Committee for Clinical Laboratory Standards. 2000. Performance standard for antimicrobial susceptibility testing; tenth informational supplement (aerobic dilution). NCCLS document M100 - S10. National Committee for Clinical Laboratory Standards, Wayne, Pa.
12. Reed, L. J., and H. Muench. 1938. A simple method of estimating fifty percent end points. Am. J. Hygiene 27:493-497.
13. Sahm, D. F., J. Kissinger, M. S. Gilmore, P. R. Murray, R. Mulder, J. Soliday, and B. Clarke. 1989. In vitro susceptibility studies of vancomycin-resistant Enterococcus faecalis. Antimicrob. Agents Chemother. 33:1588-1591.
14. Schaberg, D. R., and D. H. Culver. 1991. Major trends in the microbial etiology of nosocomial infection. Am. J. Med. 91:72S-75S.
15. Singh, K. V., K. K. Zscheek, and B. E. Murray. 2000. Efficacy of telithromycin (HMR 3647) against enterococci in a mouse peritonitis model. Antimicrob. Agents Chemother. 44:3434-3437.
16. Singh, K. V., K. Malathum, and B. E. Murray. 2001. Disruption of an Enterococcus faecium species-specific gene, a homologue of acquired macrolide resistance genes of staphylococci, is associated with an increase in macrolide susceptibility. Antimicrob. Agents Chemother. 45:263-266.
17. Singh, K. V., K. Malathum, and B. E. Murray. 2001. In vitro activities of a new ketolide, ABT-773, against multidrug-resistant gram-positive cocci. Antimicrob. Agents Chemother. 45:3640-3643.
18. von Eiff, C., and G. Peters. 2002. Comparative in vitro activity of ABT-773 and two macrolides against staphylococci. J. Antimicrob. Chemother. 49: 189-192.